These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 12815006)

  • 1. Association between two polymorphisms in the SRD5A2 gene and serum androgen concentrations in British men.
    Allen NE; Reichardt JK; Nguyen H; Key TJ
    Cancer Epidemiol Biomarkers Prev; 2003 Jun; 12(6):578-81. PubMed ID: 12815006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The association between polymorphisms in the CYP17 and 5alpha-reductase (SRD5A2) genes and serum androgen concentrations in men.
    Allen NE; Forrest MS; Key TJ
    Cancer Epidemiol Biomarkers Prev; 2001 Mar; 10(3):185-9. PubMed ID: 11303586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study.
    Hsing AW; Chen C; Chokkalingam AP; Gao YT; Dightman DA; Nguyen HT; Deng J; Cheng J; Sesterhenn IA; Mostofi FK; Stanczyk FZ; Reichardt JK
    Cancer Epidemiol Biomarkers Prev; 2001 Oct; 10(10):1077-82. PubMed ID: 11588134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5alpha-Reductase type 2 gene variant associations with prostate cancer risk, circulating hormone levels and androgenetic alopecia.
    Hayes VM; Severi G; Padilla EJ; Morris HA; Tilley WD; Southey MC; English DR; Sutherland RL; Hopper JL; Boyle P; Giles GG
    Int J Cancer; 2007 Feb; 120(4):776-80. PubMed ID: 17136762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphic markers in the 5alpha-reductase type II gene and the incidence of prostate cancer.
    Lamharzi N; Johnson MM; Goodman G; Etzioni R; Weiss NS; Dightman DA; Barnett M; DiTommaso D; Chen C
    Int J Cancer; 2003 Jul; 105(4):480-3. PubMed ID: 12712437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The 5alpha-reductase type II A49T and V89L high-activity allelic variants are more common in men with prostate cancer compared with the general population.
    Giwercman YL; Abrahamsson PA; Giwercman A; Gadaleanu V; Ahlgren G
    Eur Urol; 2005 Oct; 48(4):679-85. PubMed ID: 16039774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meta-analysis of three polymorphisms in the steroid-5-alpha-reductase, alpha polypeptide 2 gene (SRD5A2) and risk of prostate cancer.
    Li X; Huang Y; Fu X; Chen C; Zhang D; Yan L; Xie Y; Mao Y; Li Y
    Mutagenesis; 2011 May; 26(3):371-83. PubMed ID: 21177315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Importance of 5α-reductase gene polymorphisms on circulating and intraprostatic androgens in prostate cancer.
    Lévesque É; Laverdière I; Lacombe L; Caron P; Rouleau M; Turcotte V; Têtu B; Fradet Y; Guillemette C
    Clin Cancer Res; 2014 Feb; 20(3):576-84. PubMed ID: 24277450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphism of the SRD5A2 gene and the risk of prostate cancer.
    Dušenka R; Tomaškin R; Kliment J; Dobrota D; Dušenková S; Vilčková M; Sivoňová MK
    Mol Med Rep; 2014 Dec; 10(6):3151-6. PubMed ID: 25310105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum sex steroid hormone levels and polymorphisms of CYP17 and SRD5A2: implication for prostate cancer risk.
    Kakinuma H; Tsuchiya N; Habuchi T; Ohyama C; Matsuura S; Wang L; Nakamura A; Kato T
    Prostate Cancer Prostatic Dis; 2004; 7(4):333-7. PubMed ID: 15477877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of genetic polymorphisms of 17-hydroxylase cytochrome P-450 (CYP17) and steroid 5alpha-reductase type II (SRD5A2) genes on prostate-cancer risk among the Japanese population.
    Yamada Y; Watanabe M; Murata M; Yamanaka M; Kubota Y; Ito H; Katoh T; Kawamura J; Yatani R; Shiraishi T
    Int J Cancer; 2001 Jun; 92(5):683-6. PubMed ID: 11340572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Associations between polymorphisms in the steroid 5-alpha reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer.
    Salam MT; Ursin G; Skinner EC; Dessissa T; Reichardt JK
    Urol Oncol; 2005; 23(4):246-53. PubMed ID: 16018939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA.
    Makridakis NM; Ross RK; Pike MC; Crocitto LE; Kolonel LN; Pearce CL; Henderson BE; Reichardt JK
    Lancet; 1999 Sep; 354(9183):975-8. PubMed ID: 10501358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5alpha-reductase 2 polymorphisms as risk factors in prostate cancer.
    Söderström T; Wadelius M; Andersson SO; Johansson JE; Johansson S; Granath F; Rane A
    Pharmacogenetics; 2002 Jun; 12(4):307-12. PubMed ID: 12042668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular Analysis of the SRD5A1 and SRD5A2 Genes in Patients with Benign Prostatic Hyperplasia with Regard to Metabolic Parameters and Selected Hormone Levels.
    Rył A; Rotter I; Grzywacz A; Małecka I; Skonieczna-Żydecka K; Grzesiak K; Słojewski M; Szylińska A; Sipak-Szmigiel O; Piasecka M; Walczakiewicz K; Laszczyńska M
    Int J Environ Res Public Health; 2017 Oct; 14(11):. PubMed ID: 29084161
    [No Abstract]   [Full Text] [Related]  

  • 16. Single-nucleotide polymorphism in the 5-α-reductase gene (SRD5A2) is associated with increased prevalence of metabolic syndrome in chemotherapy-treated testicular cancer survivors.
    Boer H; Westerink NL; Altena R; Nuver J; Dijck-Brouwer DAJ; van Faassen M; Klont F; Kema IP; Lefrandt JD; Zwart N; Boezen HM; Smit AJ; Meijer C; Gietema JA
    Eur J Cancer; 2016 Feb; 54():104-111. PubMed ID: 26751392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. No association between the SRD5A2 gene A49T missense variant and prostate cancer risk: lessons learned.
    Pearce CL; Van Den Berg DJ; Makridakis N; Reichardt JK; Ross RK; Pike MC; Kolonel LN; Henderson BE
    Hum Mol Genet; 2008 Aug; 17(16):2456-61. PubMed ID: 18469342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of prostate cancer risk and aggressiveness to androgen pathway genes: SRD5A2, CYP17, and the AR.
    Cicek MS; Conti DV; Curran A; Neville PJ; Paris PL; Casey G; Witte JS
    Prostate; 2004 Apr; 59(1):69-76. PubMed ID: 14991867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SRD5A2 gene polymorphisms affect the risk of breast cancer.
    Francis A; Sarkar S; Pooja S; Surekha D; Rao DR; Rao L; Ramachandra L; Vishnupriya S; Satyamoorthy K; Thangaraj K; Rajender S
    Breast; 2014 Apr; 23(2):137-41. PubMed ID: 24365257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic impact of serum testosterone during androgen-deprivation therapy in patients with metastatic prostate cancer and the SRD5A2 polymorphism.
    Shiota M; Fujimoto N; Yokomizo A; Takeuchi A; Kashiwagi E; Dejima T; Kiyoshima K; Inokuchi J; Tatsugami K; Eto M
    Prostate Cancer Prostatic Dis; 2016 Jun; 19(2):191-6. PubMed ID: 26857022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.